Edwards Lifesciences Corporation
EWHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Edwards Lifesciences Corporation focuses on Medical Devices services and products. Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. With a market capitalization of $49.36B, it sits in large-cap territory. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Market Cap
$49.36B
Beta
0.85
P/E (TTM)
47.36
P/E (Fwd)
25.50
EPS (TTM)
$1.81
EPS (Fwd)
$3.36
ROE
10.5%
ROA
8.3%
Cash
$3.67B
Total Debt
$702.9M
Free CF
$902.1M
52W Change
12.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $3.67B in cash comfortably exceeding the $702.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $902.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 10.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $4.46B (2022) to $6.07B (2025), reflecting a 36% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Edwards Lifesciences Corporation's trajectory.